NCT05802836Recruiting
Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
Source: ClinicalTrials.gov · Last updated 10 Jul 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 6 Mar 2023
- Start date
- 26 Apr 2023
- Primary completion date
- Dec 2028
- Lead sponsor
- Christoph Königs
- Diseases
- Haemophilia
- NCT number
- NCT05802836
What you commit to
- Study type: Observational
- Planned participants: 100
- From 26 Apr 2023 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No therapy with emicizumab
- Immunosuppressive therapy
Other illness
- HIV-infection with CD4 (cluster of differentiation 4) cells \<200/µl
Who the study is looking for
- Severe congenital hemophilia A (CHA)
- Treatment with emicizumab irrespective of any other treatment
- Informed consent
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Frankfurt, Goethe University Coordinator of this site? Confirm its status | Frankfurt am Main | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.